BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22982189)

  • 1. Loss of TIMP-3 promotes tumor invasion via elevated IL-6 production and predicts poor survival and relapse in HPV-infected non-small cell lung cancer.
    Wu DW; Tsai LH; Chen PM; Lee MC; Wang L; Chen CY; Cheng YW; Lee H
    Am J Pathol; 2012 Nov; 181(5):1796-806. PubMed ID: 22982189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis.
    Chen PM; Cheng YW; Wang YC; Wu TC; Chen CY; Lee H
    Neoplasia; 2014 Nov; 16(11):961-71. PubMed ID: 25425970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer.
    Hsu NY; Cheng YW; Chan IP; Ho HC; Chen CY; Hsu CP; Lin MH; Chou MC
    Oncol Rep; 2009 Jan; 21(1):81-7. PubMed ID: 19082446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of interleukin-17 expression by human papillomavirus type 16 E6 in nonsmall cell lung cancer.
    Chang YH; Yu CW; Lai LC; Tsao CH; Ho KT; Yang SC; Lee H; Cheng YW; Wu TC; Shiau MY
    Cancer; 2010 Oct; 116(20):4800-9. PubMed ID: 20578176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus type 16/18 up-regulates the expression of interleukin-6 and antiapoptotic Mcl-1 in non-small cell lung cancer.
    Cheng YW; Lee H; Shiau MY; Wu TC; Huang TT; Chang YH
    Clin Cancer Res; 2008 Aug; 14(15):4705-12. PubMed ID: 18676738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting.
    Wu DW; Chuang CY; Lin WL; Sung WW; Cheng YW; Lee H
    Carcinogenesis; 2014 Aug; 35(8):1823-9. PubMed ID: 24894864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis.
    Cheng YW; Wu TC; Chen CY; Chou MC; Ko JL; Lee H
    Clin Cancer Res; 2008 Nov; 14(22):7173-9. PubMed ID: 19010833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation.
    Yun J; Park MH; Son DJ; Nam KT; Moon DB; Ju JH; Hwang OK; Choi JS; Kim TH; Jung YS; Hwang DY; Han SB; Yoon DY; Hong JT
    Cell Death Dis; 2018 Feb; 9(3):306. PubMed ID: 29467412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
    Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
    Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer.
    Wu DW; Liu WS; Wang J; Chen CY; Cheng YW; Lee H
    Clin Cancer Res; 2011 Apr; 17(7):1895-905. PubMed ID: 21325288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer.
    Wu HH; Wu JY; Cheng YW; Chen CY; Lee MC; Goan YG; Lee H
    Clin Cancer Res; 2010 Nov; 16(21):5200-10. PubMed ID: 20959404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different human papillomavirus 16/18 infection in Chinese non-small cell lung cancer patients living in Wuhan, China.
    Fei Y; Yang J; Hsieh WC; Wu JY; Wu TC; Goan YG; Lee H; Cheng YW
    Jpn J Clin Oncol; 2006 May; 36(5):274-9. PubMed ID: 16690730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
    Kikuchi S; Yamada D; Fukami T; Masuda M; Sakurai-Yageta M; Williams YN; Maruyama T; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Clin Cancer Res; 2005 Apr; 11(8):2954-61. PubMed ID: 15837747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
    Wang J; Cheng YW; Wu DW; Chen JT; Chen CY; Chou MC; Lee H
    Cancer Lett; 2006 Apr; 235(1):18-25. PubMed ID: 15935551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of p53 codon 72 genotypes and clinical outcome in human papillomavirus-infected lung cancer patients.
    Chen SP; Hsu NY; Wu JY; Chen CY; Chou MC; Lee H; Cheng YW
    Ann Thorac Surg; 2013 Apr; 95(4):1196-203. PubMed ID: 23522190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of human papillomavirus (HPV) type 16 oncoproteins promotes angiogenesis via enhancing HIF-1α and VEGF expression in non-small cell lung cancer cells.
    Li G; He L; Zhang E; Shi J; Zhang Q; Le AD; Zhou K; Tang X
    Cancer Lett; 2011 Dec; 311(2):160-70. PubMed ID: 21868151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in non-small cell lung cancer.
    Tung MC; Wu HH; Cheng YW; Wang L; Chen CY; Yeh SD; Wu TC; Lee H
    Cancer; 2013 Sep; 119(18):3367-76. PubMed ID: 23797467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
    Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
    Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
    Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
    Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.